文献速递免疫规划卫生政策与健康促进

5至40岁人群接种同源与异源BNT162b2疫苗后30天内心肌炎和心包炎发病率

Incidence rates of myocarditis and pericarditis within 30 days following homologous and heterologous BNT162b2 vaccinations in individuals 5-40 years of age.
PubMed 文献 · Vaccine · 2024-01-20

本研究利用泰国国家疫苗与保险理赔数据库,在5至40岁人群中比较同源3剂BNT162b2与异源2剂BBIBP-CorV/BNT162b2接种后30天内心肌炎和心包炎发病率,并与疫情前未免疫人群对比。同源接种后男女心肌炎和心包炎风险显著升高,异源接种后心肌炎风险未达统计学显著,心包炎事件过少无法评估。

要点

  • 同源3剂BNT162b2接种后,女性心肌炎IRR 3.09(95%CI 1.61-5.93),男性IRR 7.43(95%CI 3.11-17.73)。
  • 同源接种后女性心包炎IRR 1.84(95%CI 0.72-4.73),男性IRR 10.48(95%CI 3.90-28.15)。
  • 异源2剂BBIBP-CorV/BNT162b2后心肌炎IRR未达统计学显著,心包炎事件过少无法评估。

核心结论

  • 同源3剂BNT162b2接种后心肌炎和心包炎风险显著升高,但异源2剂BBIBP-CorV/BNT162b2接种后心肌炎风险因效力不足无法确认,心包炎事件过少无法评估。

研究设计与样本

  • 历史对照队列研究,使用泰国国家疫苗与保险理赔数据库常规记录数据,追踪2021年8月至2022年9月5至40岁人群接种后30天内事件,对照为2019年8月至10月未免疫人群月均发病率。

主要发现

  • 同源3剂BNT162b2队列7,594,965人中215例心肌炎,异源2剂BBIBP-CorV/BNT162b2队列2,914,643人中5例,未免疫人群32,424,780人中115例。
  • 同源接种后女性心肌炎IRR 3.09(95%CI 1.61-5.93),男性IRR 7.43(95%CI 3.11-17.73)。
  • 同源接种后女性心包炎IRR 1.84(95%CI 0.72-4.73),男性IRR 10.48(95%CI 3.90-28.15)。
  • 异源接种后心肌炎IRR女性2.24(95%CI 0.70-7.17)、男性1.99(95%CI 0.48-8.21),均未达统计学显著。
  • 异源接种后心包炎因观察事件数过少无法获得IRR。

关键数值与推荐

  • 同源3剂BNT162b2接种后女性心肌炎IRR 3.09(95%CI 1.61-5.93),男性IRR 7.43(95%CI 3.11-17.73)。
  • 同源3剂BNT162b2接种后女性心包炎IRR 1.84(95%CI 0.72-4.73),男性IRR 10.48(95%CI 3.90-28.15)。
  • 异源2剂BBIBP-CorV/BNT162b2接种后女性心肌炎IRR 2.24(95%CI 0.70-7.17),男性IRR 1.99(95%CI 0.48-8.21),均未达统计学显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究因效力不足无法确认异源2剂BBIBP-CorV/BNT162b2接种后心肌炎风险是否增加。
  • 异源接种后心包炎事件过少无法评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Due to the data scarcity in low- and middle-income countries, we aimed to examine the incidence rate of myocarditis and pericarditis within 30 days after each dose of homologous (3 × BNT162b2) and heterologous prime-boost (2 × BBIBP-CorV/BNT162b2) vaccine regimen among individuals younger than 40 years. METHODS: We conducted a historical control cohort using routinely recorded data from Thai national vaccine and insurance claims databases. Sex-specific incidence rate ratios (IRRs) for myocarditis and pericarditis were calculated for each vaccination strategy and contrasted with incidence rates among the non-immunised population in the pre-COVID-19 period. From August 2021 to September 2022, we tracked the incidence of myocarditis and pericarditis within 30 days after vaccinations using < 40-year-old national population databases. Our reference was the average monthly incidence of these conditions in the non-immunised population from August to October 2019. The exposure of interest was immunisation against the SARS-CoV-2 virus, incorporating the following vaccination strategies: three-dose 3 × BNT162b2 regimen, three-dose 2 × BBIBP-CorV/BNT162b2 regimen, and non-immunisation. RESULTS: For myocarditis, a total of 215 cases were identified among 7,594,965 individuals in the 3 × BNT162b2 cohort, 5 cases among 2,914,643 individuals in the 2 × BBIBP-CorV/BNT162b2 cohort, and 115 cases among 32,424,780 non-immunised individuals. The sex-specific IRRs (95 % confidence intervals) of myocarditis and pericarditis after the homologous vaccination were 3.09 (1.61, 5.93) and 1.84 (0.72, 4.73) for females and 7.43 (3.11, 17.73) and 10.48 (3.90, 28.15) for males, respectively. Conversely, the IRRs of myocarditis after the heterologous vaccination were not significant (females: 2.24 (0.70, 7.17); males: 1.99 (0.48, 8.21)). IRRs could not be obtained for pericarditis after the heterologous vaccination because of the small number of observed events. CONCLUSIONS: The study observed a significantly increased risk of myocarditis and pericarditis following homologous 3 × BNT162b2 vaccination but had insufficient power to confirm an increased risk for myocarditis following the heterologous prime-boost 2 × BBIBP-CorV/BNT162b2 vaccination. The incidence of pericarditis following the heterologous vaccination was too rare to evaluate.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kumwichar P, Chongsuvivatwong V, Vasoppakarn S, et al. Incidence rates of myocarditis and pericarditis within 30 days following homologous and heterologous BNT162b2 vaccinations in individuals 5-40 years of age. Vaccine. 2024. PMID: 38246843. doi:10.1016/j.vaccine.2024.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。